Early relapses after the first dose of natalizumab in active multiple sclerosis patients

Abstract

Background

Natalizumab is prescribed in Italy in patients who experienced at least two clinical relapses during a 12-month therapy with other approved immunomodulatory agents.

Results

In 7 of 35 patients selected on the basis of these recommendations, we have observed clinical relapses occurring within 24 h after the first dose of natalizumab.

Conclusion

The mechanism by which a first injection of natalizumab may precipitate a clinical relapse in patients with MS is unknown. We speculate that natalizumab can promote the release of inflammatory mediators from lymphocytes present in the central nervous system at the time of the first infusion, thus favoring the clinical manifestation of a pre-existing active lesion.

Keywords

monoclonal antibody VLA-4 tysabri

Get full access to this article

View all access options for this article.

References

1 Polman CH O’Connor PW Havrdova E . AFFIRM investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899–910.

2 Rudick RA Stuart WH Calabresi PA . SENTINEL investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911–923.

3 Balcer LJ Galetta SL Calabresi PA . Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology 2007; 68: 1299–1304.

4 Mareckova H Havrdova E Krasulova E Vankova Z Koberová M Sterzl I . Natalizumab in the treatment of patients with multiple sclerosis: first experience. Ann N Y Acad Sci 2007; 1110: 465–473.

5 Rudick RA Miller D Hass S . AFFIRM and SENTINEL investigators. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 2007; 62: 335–346.

6 Ransohoff RM . Thinking without thinking" about natalizumab and PML. J Neurol Sci 2007; 259: 50–52.

7 Vellinga MM; Castelijns JA; Barkhof F; Uitdehaag BM; Polman CH; . Postwithdrawal rebound increase in t2 lesional activity in natalizumab-treated MS patients. Neurology 2008; 70: 1150–1151.

8 Calabresi PA Giovannoni G Confavreux C . AFFIRM and SENTINEL investigators. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007; 69: 1391–1403.

9 Humphries MJ . Monoclonal antibodies as probes of integrin priming and activation. Biochem Soc Trans 2004; 32: 407–411.

10.

10 Hauser SL Waubant E Arnold DL . HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676–688.